A final report by the UN's high-level advisory body on artificial intelligence makes for, at times, a surreal read. Named ...

PP02.05 Initial Results from RESOLVE, a Phase 1b Dose-Escalation Study of EP-104GI (Extended-Release Fluticasone ...

Idorsia Ltd (SIX: IDIA) today announced that new data and analyses of daridorexant, Idorsia’s dual orexin receptor antagonist ...

The Mesh MEA™ platform is currently being evaluated at select test sites for neurological and cardiac research in addition to safety pharmacology and toxicology applications. The Company has also ...

A coordinated effort called “National Only Citizens Vote” has been rolled out this week by a coalition of people pushing ...

Wittenberg University and Clark State College have moved classes online for the week as dishonest rumors about migrants ...

First whale sighting contest begins Whatʻs your best guess? Whale season will be here in Hawaiʻi before you know it. When do ...

DAYBREAK was a Phase 3, multi-center, long-term open-label extension study to evaluate the safety and efficacy of Zeposia (ozanimod) administered orally to patients with relapsing forms of multiple ...

ImmVira announced the latest clinical results for its lead oncolytic virus product, MVR-T3011, via intravesical ...

The latest research and advances in otolaryngology-head and neck surgery will be presented during the AAO-HNSF 2024 Annual Meeting & OTO EXPOSM in Miami, Florida, September 28 – October 1.

The presented posters “ Advancing a multi-dimension KRAS mutation-specific T cell receptor (TCR) library with a 3S TCR targeting the G12D mutation to address large global patient populations ” and “ ...